ArticleOncoTargets and therapy2018
Prognostic and clinicopathological value of SIRT3 expression in various cancers: a systematic review and meta-analysis.
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Prognostic significance of lncRNA DANCR expression in human cancers: a systematic review and meta-analysis.Bioscience reports · 2021Pooled it
- Prognostic value of CD44v9 expression in human cancers: A systematic review and meta-analysis.Medicine · 2020Pooled it
- Prognostic significance of red blood cell distribution width in gastrointestinal cancers: A meta-analysis.Medicine · 2020Pooled it
- Prognostic significance of LncRNA GHET1 expression in various cancers: a systematic review and meta-analysis.Bioscience reports · 2019Pooled it
- SIRT3 suppresses renal cancer progression by regulating IDH2 acetylation.Scientific reports · 2026Article
- Role of SIRT3 in digestive system diseases and therapeutic prospects (Review).International journal of molecular medicine · 2026Review
- Emerging role of sirtuins in non‑small cell lung cancer (Review).Oncology reports · 2024Review
- SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells.Cellular & molecular biology letters · 2024Article
- Evaluation of ARK5 and SIRT3 expression in renal cell carcinoma and their clinical significance.Diagnostic pathology · 2023Article
- Photochemical Targeting of Mitochondria to Overcome Chemoresistance in Ovarian CancerPhotochemistry and photobiology · 2023Review
- Article
- Mitochondrial Sirt3 serves as a biomarker for sepsis diagnosis and mortality prediction.Scientific reports · 2022Article
- Prognostic value of nicotinamideOpen medicine (Warsaw, Poland) · 2022Article
- SIRT3 and Metabolic Reprogramming Mediate the Antiproliferative Effects of Whey in Human Colon Cancer Cells.Cancers · 2021Article
- Role of lncRNA-ATB in ovarian cancer and its mechanisms of action.Experimental and therapeutic medicine · 2020Article
- Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells.Oncogene · 2020Article
- Integrative Analysis of Sirtuins and Their Prognostic Significance in Clear Cell Renal Cell Carcinoma.Frontiers in oncology · 2020Article
- Review
- Controversial Impact of Sirtuins in Chronic Non-Transmissible Diseases and Rehabilitation Medicine.International journal of molecular sciences · 2018Review
- SIRT3 a Major Player in Attenuation of Hepatic Ischemia-Reperfusion Injury by Reducing ROS via Its Downstream Mediators: SOD2, CYP-D, and HIF-1Oxidative medicine and cellular longevity · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral studies have explored the prognostic value of sirtuin 3 (SIRT3) in various cancers, but obtained inconsistent results. The current systematic review and meta-analysis was conducted to investigate the association between SIRT3 expression and prognosis in various cancers.
methodsPubMed, Embase, Web of Science and the Cochrane Library were comprehensively retrieved by the end of September 29, 2017. All the relevant studies were checked and included in the meta-analysis if they met the inclusion criteria.
resultsA total of 17 studies involving 2,865 patients were included in the systematic review and meta-analysis. The results indicated that SIRT3 expression was not significantly associated with overall survival (OS) (hazard ratio [HR]=0.87, 95% CI=0.59-1.29,
conclusionSIRT3 was distinctly related to the OS in specific cancers. SIRT3 was an unfavorable prognostic factor in BC, CC and NSCLC; however, it was also a favorable prognostic factor in CLL, HCC, PC and RCC, especially in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.